Charles Schwab
BOLT icon

Charles Schwab’s Bolt Biotherapeutics BOLT Stock Holding History

Charles Schwab’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,236
Closed -$34.4K – 3620
2023
Q1 		$34.4K Buy
+1,236
New +$36.2K ﹤0.01% 3422
2022
Q2 		– Sell
-2,543
Closed -$140K – 3552
2022
Q1 		$140K Sell
2,543
-208
-8% -$14K ﹤0.01% 3362
2021
Q4 		$270K Buy
2,751
+133
+5% +$25.2K ﹤0.01% 3300
2021
Q3 		$663K Sell
2,618
-1,226
-32% -$346K ﹤0.01% 3045
2021
Q2 		$1.19M Sell
3,844
-200
-5% -$81.2K ﹤0.01% 2866
2021
Q1 		$2.66M Buy
+4,044
New +$2.63M ﹤0.01% 2580

Other funds holding BOLT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Charles Schwab's BOLT Position: Q2 2023 in Review

Charles Schwab sold out of Bolt Biotherapeutics (BOLT) in Q2 2023, closing a stake of 1,236 shares — an estimated $34.4K sold.

Charles Schwab first reported a position in BOLT in Q1 2021 and held it in 6 quarters. The position peaked at $2.66M in Q1 2021. 40 funds tracked by Wall St. Rank hold BOLT as of Q2 2023.

  • Charles Schwab reported no remaining Bolt Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Charles Schwab sold 1,236 Bolt Biotherapeutics shares in Q2 2023, an estimated $34.4K.
  • Charles Schwab first reported a position in Bolt Biotherapeutics in Q1 2021 and held it in 6 quarters.
  • Charles Schwab's Bolt Biotherapeutics position peaked at $2.66M in Q1 2021.
  • 40 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2023.

Based on Charles Schwab's 13F filing for Q2 2023, filed 10 Aug 2023.